Literature DB >> 16125528

Impact of glucagon response on postprandial hyperglycemia in men with impaired glucose tolerance and type 2 diabetes mellitus.

Elena Henkel1, Mario Menschikowski, Carsta Koehler, Wolfgang Leonhardt, Markolf Hanefeld.   

Abstract

Glucagon is the physiological antagonist of insulin. Postprandial (pp) hyperglycemia in impaired glucose tolerance (IGT) and in type 2 diabetes mellitus (T2DM) may also depend on irregularities in glucagon secretion. This study investigated the glucagon excursion after a lipid-glucose-protein tolerance test in subjects with different stages of glucose intolerance. We also analyzed the relationship between pp glucagon secretion and hyperglycemias. A total of 64 men (27 healthy subjects with normal glucose tolerance [NGT], 15 with IGT, and 22 with T2DM) were examined. Plasma glucose (PG), insulin, proinsulin, free fatty acids, and triglycerides were measured in the fasting state and at 30 minutes and 2, 3, 4, and 6 hours after the intake of the test meal, which contained 126 g carbohydrates, 92 g fat, and 17 g protein. Postprandial concentrations of metabolic parameters were calculated as area under the curve (AUC). Glucagon was measured in the fasting state and at 30 minutes and 2 and 4 hours pp. Early glucagon increment was defined as glucagon at 30 minutes minus fasting glucagon. The insulin response was quantified as insulin increment divided by PG increment in the corresponding time. Insulin resistance was calculated using lomeostasis model assessment (HOMA). Fasting glucagon was significantly increased in IGT vs NGT (P<.05), and early glucagon increment was significantly higher in T2DM vs NGT and IGT (P<.05). The 2-hour glucagon concentration after the load (AUC) was increased in IGT and T2DM vs NGT (P<.05). Early glucagon increment and the 2-hour AUC of glucagon were strongly correlated to pp glycemia (r=0.494 and P=.001, and r=0.439 and P=.003, respectively). An inverse correlation was observed between early glucagon increment and insulin response at 30 minutes and 2 hours after the meal load (r=-0.287 and P=.026, and r=-0.435 and P=.001, respectively). The 2-hour AUC of glucagon was significantly associated with insulin resistance (r=0.354, P=.020). Multivariate analysis revealed 2-hour insulin response and early glucagon increment as significant independent determinants of the AUC of PG in IGT (R=0.787). In T2DM, 2-hour insulin response, insulin resistance, and early glucagon increment were significant determinants of the AUC of PG (R=0.867). Our study suggests an important role for the irregularities in glucagon response in the pp glucose excursion after a standardized oral mixed meal in IGT and in T2DM. According to our data, a bihormonal imbalance starts before diabetes is diagnosed. Prospective studies are needed to evaluate the impact of glucagon on the progression of glucose intolerance and the possible effects of medicinal suppression of glucagon increment to prevent the progression of glucose tolerance.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16125528     DOI: 10.1016/j.metabol.2005.03.024

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  15 in total

1.  Kinetic modeling of human hepatic glucose metabolism in type 2 diabetes mellitus predicts higher risk of hypoglycemic events in rigorous insulin therapy.

Authors:  Matthias König; Hermann-Georg Holzhütter
Journal:  J Biol Chem       Date:  2012-09-12       Impact factor: 5.157

2.  Pathophysiology and aetiology of impaired fasting glycaemia and impaired glucose tolerance: does it matter for prevention and treatment of type 2 diabetes?

Authors:  K Faerch; K Borch-Johnsen; J J Holst; A Vaag
Journal:  Diabetologia       Date:  2009-07-10       Impact factor: 10.122

Review 3.  Glucagon, cyclic AMP, and hepatic glucose mobilization: A half-century of uncertainty.

Authors:  Robert L Rodgers
Journal:  Physiol Rep       Date:  2022-05

4.  Impact of reduced meal frequency without caloric restriction on glucose regulation in healthy, normal-weight middle-aged men and women.

Authors:  Olga Carlson; Bronwen Martin; Kim S Stote; Erin Golden; Stuart Maudsley; Samer S Najjar; Luigi Ferrucci; Donald K Ingram; Dan L Longo; William V Rumpler; David J Baer; Josephine Egan; Mark P Mattson
Journal:  Metabolism       Date:  2007-12       Impact factor: 8.694

5.  Targeting Incretins in Type 2 Diabetes: Role of GLP-1 Receptor Agonists and DPP-4 Inhibitors.

Authors:  Richard E Pratley; Matthew Gilbert
Journal:  Rev Diabet Stud       Date:  2008-08-10

6.  The effect of DPP-4 inhibition with sitagliptin on incretin secretion and on fasting and postprandial glucose turnover in subjects with impaired fasting glucose.

Authors:  Gerlies Bock; Chiara Dalla Man; Francesco Micheletto; Rita Basu; Paula D Giesler; Jeanette Laugen; Carolyn F Deacon; Jens J Holst; Gianna Toffolo; Claudio Cobelli; Robert A Rizza; Adrian Vella
Journal:  Clin Endocrinol (Oxf)       Date:  2009-12-18       Impact factor: 3.478

7.  Quantifying the contribution of the liver to glucose homeostasis: a detailed kinetic model of human hepatic glucose metabolism.

Authors:  Matthias König; Sascha Bulik; Hermann-Georg Holzhütter
Journal:  PLoS Comput Biol       Date:  2012-06-21       Impact factor: 4.475

8.  Choline Deficiency Attenuates Body Weight Gain and Improves Glucose Tolerance in ob/ob Mice.

Authors:  Gengshu Wu; Liyan Zhang; Tete Li; Gary Lopaschuk; Dennis E Vance; René L Jacobs
Journal:  J Obes       Date:  2012-06-18

9.  Too much glucagon, too little insulin: time course of pancreatic islet dysfunction in new-onset type 1 diabetes.

Authors:  Rebecca J Brown; Ninet Sinaii; Kristina I Rother
Journal:  Diabetes Care       Date:  2008-07       Impact factor: 19.112

10.  Postabsorptive hyperglucagonemia in patients with type 2 diabetes mellitus analyzed with a novel enzyme-linked immunosorbent assay.

Authors:  Toshihiro Matsuo; Jun-Ichiro Miyagawa; Yoshiki Kusunoki; Masayuki Miuchi; Takashi Ikawa; Takafumi Akagami; Masaru Tokuda; Tomoyuki Katsuno; Akira Kushida; Takashi Inagaki; Mitsuyoshi Namba
Journal:  J Diabetes Investig       Date:  2015-08-24       Impact factor: 4.232

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.